Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.

ABSTRACT:

Objectives

To report the final results of the 2-year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry®/BAY 81-8973) used in standard clinical practice in patients with moderate-to-severe haemophilia A.

Methods

TAURUS (NCT02830477) is a phase 4, multinational, prospective, non-interventional, single-arm study in patients of any age with moderate or severe haemophilia A (≤5% factor [F]VIII activity). TAURUS was designed to primarily investigate weekly prophylaxis dosing regimens used in standard clinical practice. Annualised bleeding rates (ABRs), treatment satisfaction and adherence, and safety were also assessed.

Results

Of 302 patients included in the full analysis set, 84.4% (n = 255) maintained their octocog alfa prophylaxis base

SUBMITTER: Santoro C 

PROVIDER: S-EPMC10092432 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature